PubReading [6] Will CRISPR‐Cas9 Have Cards to Play Against Cancer? An Update on its Applications - P Daisy, K Shreyas, T. S. Anitha - Molecular Biotechnology

<p><strong>Genome editing</strong> employs targeted nucleases as <strong>powerful tools</strong> to precisely alter the genome of target cells and regulate functional genes. Various strategies have been risen so far as the molecular scissors-mediated genome editing that includes zinc finger nuclease, transcription activator-like effector nucleases, and clustered regularly interspaced short palindromic repeats—<strong>CRISPR</strong>-related protein 9. These tools allow researchers to understand the basics of manipulating the genome, create animal models to study human diseases, understand host–pathogen interactions and design disease targets. Targeted genome modification utilizing <strong>RNA-guided nucleases</strong> are of recent curiosity, as it is a fast and effective strategy that enables the researchers to manipulate the gene of interest, carry out functional studies, understand the molecular basis of the disease and design targeted therapies. CRISPR-Cas9, a bacterial defense system employed against viruses, consists of a single-strand RNA-guided Cas9 nuclease connected to the corresponding complementary target sequence. This powerful and versatile tool has gained tremendous attention among the researchers, owing to its ability to correct genetic disorders. To help illus- trate the potential of this gene editor in unexplored corners of <strong>oncology</strong>, we describe the history of <strong>CRISPR-Cas9</strong>, its rapid progression in <strong>cancer research</strong> as well as future perspectives. - P Daisy, K Shreyas, T. S. Anitha -doi.org/10.1007/s12033-020-00289-1 - 2021</p>